SIC
CRSP icon

SFE Investment Counsel’s CRISPR Therapeutics CRSP Stock Holding History

SFE Investment Counsel’s Portfolio CRSP Stock Details CRSP Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q2 		$6.23M Buy
+16,700
New +$880K 0.84% 47

Other funds holding CRSP

BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $3.37T AUM 44.26% 1-Year Est. Return
Sumitomo Mitsui Trust Group
Sumitomo Mitsui Trust Group Minato-Ku, Tokyo, Japan $175B AUM 40.63% 1-Year Est. Return
IEFM
IQ EQ Fund Management Dublin 2, Ireland $1.57B AUM 40.42% 1-Year Est. Return
Bank of New York Mellon
Bank of New York Mellon New York $609B AUM 40.19% 1-Year Est. Return
LPL Financial
LPL Financial San Diego, California $445B AUM 25.58% 1-Year Est. Return
Pictet Asset Management
Pictet Asset Management Carouge, Switzerland $105B AUM 38.07% 1-Year Est. Return
TD Asset Management
TD Asset Management Toronto, Ontario, Canada $115B AUM 41.58% 1-Year Est. Return
KBC Group
KBC Group Brussels, Belgium $46.3B AUM 43.9% 1-Year Est. Return
Citigroup
Citigroup New York $303B AUM 53.02% 1-Year Est. Return

SFE Investment Counsel's CRSP Position: Q2 2026 in Review

SFE Investment Counsel increased its CRISPR Therapeutics (CRSP) stake by 16% in Q2 2026, buying an estimated $118K and bringing the position to 16,365 shares worth $893K. The position accounts for 0.12% of the portfolio, ranked #97.

SFE Investment Counsel first reported a position in CRSP in Q4 2023 and has held it in 11 quarters since. 252 funds tracked by Wall St. Rank hold CRSP as of Q2 2026.

  • SFE Investment Counsel held 16,365 shares of CRISPR Therapeutics worth $893K as of Q2 2026.
  • SFE Investment Counsel bought 2,245 CRISPR Therapeutics shares in Q2 2026, an estimated $118K.
  • CRISPR Therapeutics made up 0.12% of SFE Investment Counsel's portfolio in Q2 2026, its #97 holding.
  • SFE Investment Counsel first reported a position in CRISPR Therapeutics in Q4 2023 and has held it in 11 quarters since.
  • 252 funds tracked by Wall St. Rank held CRISPR Therapeutics as of Q2 2026.

Based on SFE Investment Counsel's 13F filing for Q2 2026, filed 5 Aug 2026.